KRYSTAL BIOTECH DL-,00001

Krystal Biotech’s stock rose to an all-time high of around $316.53, giving it a market capitalization of about $9.25 billion. Over the past year the stock gained 138.49%; InvestingPro currently rates it as slightly overvalued. Krystal reported a strong first quarter with earnings per share of $1.83 (expectation $1.48) and revenue of $116.4 million, beating both BofA and consensus estimates; BofA nonetheless marginally cut its price target from $325 to $323 and confirmed its buy recommendation. » More on de.investing.com

Krystal Biotech reported Q1 2026 EPS of $1.83 (estimate $1.48) and revenue of $116.4 million, with both metrics beating expectations. Net income rose 56.6% to $55.9 million and gross margin improved to 95%. The stock fell about 2.3% in premarket trading despite the results. For Q2 and Q3 2026 the company guides to EPS of $1.86 and $2.21 and revenues of $126.45 million and $142.5 million, but cites risks from price negotiations in Europe, higher operating costs and potential market saturation in the US. » More on de.investing.com

Krystal Biotech has turned profitable and grew 2025 revenue 34% to $389.1 million, driven by Vyjuvek, the first FDA-approved therapy for dystrophic epidermolysis bullosa. The company targets modest patient populations in the U.S., Japan and parts of Europe and is developing additional gene-therapy candidates including KB407 and KB408. Sustaining multidecade, life-changing returns would require successful launches of these pipeline drugs and protection of pricing power amid potential competition and clinical or regulatory risks. » More on finance.yahoo.com